Physician profile
Esther Guy
NPI 1740399484
$9,734.97
in general payments reported to CMS, 2019-2025
44 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $1,368 · 2021: $1,549 · 2022: $1,239 · 2023: $2,048 · 2024: $1,557 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,697 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,696.67 |
| Education | $188.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,748.16 | 2019-2025 | Evenity, Repatha, Repatha |
| Lilly USA, LLC | $1,247.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $789.38 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $689.27 | 2020-2025 | |
| Harmony Biosciences LLC | $432.68 | 2023-2025 | Wakix |
| Esperion Therapeutics, INC. | $394.75 | 2021-2025 | Nexletol, Nexlizet |
| Amarin Pharma, INC. | $390.96 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $374.31 | 2022-2025 | Quviviq, Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $357.10 | 2019-2025 | Xifaxan, Trulance |
| Vanda Pharmaceuticals INC. | $318.92 | 2022-2023 | Hetlioz |
| Jazz Pharmaceuticals INC. | $261.53 | 2021-2023 | Xywav |
| Allergan, INC. | $252.75 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $251.56 | 2019-2023 | Livalo, Seglentis |
| Astrazeneca Pharmaceuticals LP | $248.22 | 2019-2022 | |
| Pfizer INC. | $238.49 | 2021-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $210.77 | 2019-2025 | Unithroid |
| Glaxosmithkline, LLC. | $205.87 | 2023-2024 | Arexvy, Shingrix, Fluarix Quadrivalent |
| Corcept Therapeutics | $144.27 | 2025 | Korlym |
| Genentech USA, INC. | $92.54 | 2019-2021 | |
| Astellas Pharma US INC | $90.53 | 2020-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $78.77 | 2019-2021 | |
| Antares Pharma, INC. | $72.31 | 2021-2022 | |
| Agepha Pharma Fz LLC | $72.07 | 2024 | Lodoco |
| Exact Sciences Corporation | $63.01 | 2023-2025 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $61.05 | 2020-2025 | Tirosint, Licart, Flector |
| Eisai INC. | $60.06 | 2021 | |
| Dexcom, INC. | $49.03 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.76 | 2020-2025 | Ofev |
| Cleerly, INC. | $45.70 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Merck Sharp & Dohme LLC | $45.31 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $44.70 | 2024 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $41.55 | 2021 | |
| Paratek Pharmaceuticals, INC. | $39.67 | 2025 | Nuzyra, Xhance |
| Inspire Medical Systems, INC. | $39.28 | 2023 | Inspire |
| Azurity Pharmaceuticals, INC. | $37.41 | 2024 | Horizant |
| Arbor Pharmaceuticals, INC. | $32.26 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.23 | 2019 | |
| Axsome Therapeutics, INC. | $25.56 | 2024 | Sunosi |
| Medicure Pharma INC. | $24.93 | 2021 | |
| Medtronic, INC. | $24.89 | 2023 | Venaseal |
| Tolmar, INC. | $23.94 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $13.63 | 2019 | |
| Vivus LLC | $12.88 | 2019 | |
| Vistapharm, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Guy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.